AG
VNDA icon

Aperio Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Aperio Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$600K Buy
45,669
+12,007
+36% +$145K ﹤0.01% 1870
2020
Q3 		$325K Buy
33,662
+641
+2% +$6.85K ﹤0.01% 2036
2020
Q2 		$378K Buy
33,021
+8,392
+34% +$95K ﹤0.01% 1908
2020
Q1 		$255K Buy
24,629
+7,405
+43% +$91.8K ﹤0.01% 1994
2019
Q4 		$283K Buy
17,224
+4,904
+40% +$74.1K ﹤0.01% 2088
2019
Q3 		$164K Buy
12,320
+2,649
+27% +$36.9K ﹤0.01% 2197
2019
Q2 		$136K Sell
9,671
-800
-8% -$12.7K ﹤0.01% 2299
2019
Q1 		$193K Sell
10,471
-971
-8% -$22.1K ﹤0.01% 2174
2018
Q4 		$299K Buy
+11,442
New +$269K ﹤0.01% 1947

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Aperio Group's VNDA Position: Q4 2020 in Review

Aperio Group increased its Vanda Pharmaceuticals (VNDA) stake by 36% in Q4 2020, buying an estimated $145K and bringing the position to 45,669 shares worth $600K. The position accounts for ﹤0.01% of the portfolio, ranked #1870.

Aperio Group first reported a position in VNDA in Q4 2018 and has held it in 9 quarters since. 178 funds tracked by Wall St. Rank hold VNDA as of Q4 2020.

  • Aperio Group held 45,669 shares of Vanda Pharmaceuticals worth $600K as of Q4 2020.
  • Aperio Group bought 12,007 Vanda Pharmaceuticals shares in Q4 2020, an estimated $145K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1870 holding.
  • Aperio Group first reported a position in Vanda Pharmaceuticals in Q4 2018 and has held it in 9 quarters since.
  • 178 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.